CLINICAL_TRIALS trial_result · 2012-07-27

Clinical Trial Update: A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma [Phase 2]

Phase II trial of P276-00 for relapsed or refractory mantle cell lymphoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Piramal Enterprises Limited | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2012-07-27